Mylan strikes Humira biosim delay deal with AbbVie

In an effort to protect its Humira patent, AbbVie signed an agreement to grant Mylan the rights to begin marketing its biosimilar in the United States.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news